Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 19/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29825742 | 1.00 | KLKB1 (0.53) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL18623226 | 1.00 | KLKB1 (0.53) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL17064666 | 1.00 | KLKB1 (0.53) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL22967743 | 0.88 | KLKB1 (0.53) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL29581238 | 0.86 | KLKB1 (0.50) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL17064855 | 0.86 | KLKB1 (0.50) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL18623229 | 0.86 | KLKB1 (0.50) | KLKB1PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL17064891 | 0.85 | KLKB1 (0.50) | KLKB1 | |
| SCHEMBL17073530 | 0.85 | KLKB1 (0.50) | KLKB1 | |
| SCHEMBL17064664 | 0.82 | KLKB1 (0.51) | KLKB1PLGPRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591212-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| CN-114591212-A | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-108289893-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100082-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | KLKB1 1/4885PLG 32/4885PRSS1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.